Richard Crawford, MD
Endocrinology, Diabetes & Metabolism · Sioux Falls, SDNPI 1164528261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,578 of the $126,021 with a category attached, or 90.1%. 22 manufacturers reported payments, led by Novo Nordisk at 58.9% of the total. Reporting peaked in 2019 at $39,349 and has fallen 55.0% since, to $17,711 in 2025.
Across 206 payments — averaging $611.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$74K
- Boehringer Ingelheim$15K
- Johnson & Johnson$12K
- AstraZeneca$10K
- Lilly USA, LLC$10K
- Sanofi-aventis U.S. LLC$5K
- plus $1K from 16 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$113,57890%
- Travel & lodging$5,9205%
- Food & beverage$3,4903%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $74,225 |
| Boehringer Ingelheim | 33 | $14,634 |
| Johnson & Johnson | 17 | $11,825 |
| AstraZeneca | 11 | $9,865 |
| Lilly USA, LLC | 17 | $9,747 |
| Sanofi-aventis U.S. LLC | 8 | $4,654 |
| Amgen(2 entities) | 10 | $287 |
| Medtronic | 7 | $217 |
| Pfizer | 5 | $129 |
| Novartis | 3 | $74 |
| Ascendis Pharma Endocrinology Inc | 3 | $47 |
| Chiesi USA, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $38 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Abbott | 2 | $27 |
| Almatica Pharma LLC | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| BETA Bionics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$34,032
- RYBELSUS$26,744
- JARDIANCE$23,810
- INVOKANA$11,700
- FARXIGA$9,853
- Tresiba$8,560
- SOLIQUA 100/33$3,130
- TOUJEO$1,476
- MINIMED 780G$133
- TEPEZZA$124
How this compares
$126,021 in reported general payments places this provider in the 85th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
See all endocrinology, diabetes & metabolism providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 238 | $248,256 |
| JardianceEmpagliflozin | 241 | $214,025 |
| MounjaroTirzepatide | 186 | $202,982 |
| Tresiba Flextouch U-200Insulin Degludec | 113 | $190,603 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $121,520 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 100 | $110,151 |
| TrulicityDulaglutide | 62 | $86,622 |
| Novolog FlexpenInsulin Aspart | 276 | $77,261 |
| Tresiba Flextouch U-100Insulin Degludec | 134 | $72,063 |
| FarxigaDapagliflozin Propanediol | 71 | $63,378 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 88 | $37,420 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $34,667 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $33,352 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 21 | $31,901 |
| FiaspInsulin Aspart (Niacinamide) | 16 | $28,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog, Rybelsus | $74,225 | $343,142347 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $9,747 | $295,463293 claims |
| Boehringer IngelheimJardiance | $14,634 | $214,025241 claims |
| AstraZenecaFarxiga | $9,865 | $63,37871 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $4,654 | $41,58178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
Other endocrinology, diabetes & metabolism in Sioux Falls
- Brandon AllardSioux Falls$3K
- Randall FennerSioux Falls$2K
- Marie Angelica DiazSioux Falls$2K
- Hassan MehmoodSioux Falls$1K
- Lorayne ChuaSioux Falls$1K
- Marcio GriebelerSioux Falls$1K
- Anthony SallarSioux Falls$921
- Nour Aljariri AlhesanSioux Falls$558
- Natalie KappusSioux Falls$526
- Racquel Anel-TiangcoSioux Falls$506
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.